Changes in APP metabolism plays a key role in the long-term action of acetylcholinesterase (AChE) inhibitors [3, 12], and the level of acetylcholine (ACh) in AD brain tissues is significantly reduced [13]. Here, APP is linked to Alzheimer disease.